This virtual public meeting with the FDA will provide further insight into the scientific evidence suggesting the presence or absence of sex and gender differences in use and responses to CBD and other cannabinoids. Conditions for which CBD is often marketed, such as chronic pain, anxiety, depression, and sleep disturbances, are more prevalent in women than men. Therefore, consideration of issues pertaining to the safety of CBD products may be particularly important to address in women. In addition, use of CBD and other cannabinoids during pregnancy is an important public health concern that will be highlighted at this meeting.
You can register here > https://collaborationcqpub1.fda.gov/content/connect/c1/7/en/events/event/shared/default_template/event_registration.html?_charset_=utf-8&sco-id=194489245&utm_medium=email&utm_source=govdelivery
Thu, November 19, 2020
9:00am - 4:00pm